首页 / 院系成果 / 成果详情页

Multitargeted Immunomodulatory Therapy for Viral Myocarditis by Engineered Extracellular Vesicles 期刊论文 WOS高被引论文 WOS热点论文

编号：

A03AE5BC4AEFBA2B56FFEE5DAFEC8C6F
作者：

Pei, Weiya(裴纬亚)#^[1,3,5]Zhang, Yingying(张莺莺)#^[4]Zhu, Xiaolong(朱小龙)#^[1,3,5]Zhao, Chen^[2];Li, Xueqin(李雪琴)^[1,3,5]Lu'''', Hezuo(吕合作)*^[6,7]Lv, Kun(吕坤)*^[1,3,5]
语种：

英文
期刊：

ACS NANO ISSN：1936-0851 2024 年 18 卷 4 期 (2782 - 2799) ; JAN 17
收录：
关键词：

Macrophages Platelet membranes Extracellularvesicles Viral myocarditis Immunomodulation
摘要：

Immune regulation therapies are considered promising for treating classically activated macrophage (M1)-driven viral myocarditis (VM). Alternatively, activated macrophage (M2)-derived extracellular vesicles (M2 EVs) have great immunomodulatory potential owing to their ability to reprogram macrophages, but their therapeutic efficacy is hampered by insufficient targeting capacity in vivo. Therefore, we developed cardiac-targeting peptide (CTP) and platelet membrane (PM)-engineered M2 EVs enriched with viral macrophage inflammatory protein-II (vMIP-II), termed CTP/PM-M2 EVs(vMIP-II-Lamp2b), to improve the delivery of EVs "cargo" to the heart tissues. In a mouse model of VM, the intravenously injected CTP/PM-M2 EVs(vMIP-II-Lamp2b) could be carried into the myocardium via CTP, PM, and vMIP-II. In the inflammatory microenvironment, macrophages differentiated from circulating monocytes and macrophages residing in the heart showed enhanced endocytosis rates for CTP/PM-M2 EVs(vMIP-II-Lamp2b). Subsequently, CTP/PM-M2 EVs(vMIP-II-Lamp2b) successfully released functional M2 EVs(vMIP-II-Lamp2b) into the cytosol, which facilitated the reprogramming of inflammatory M1 macrophages to reparative M2 macrophages. vMIP-II not only helps to increase the targeting ability of M2 EVs but also collaborates with M2 EVs to regulate M1 macrophages in the inflammatory microenvironment and downregulate the levels of multiple chemokine receptors. Finally, the cardiac immune microenvironment was protectively regulated to achieve cardiac repair. Taken together, our findings suggest that CTP-and-PM-engineered M2 EVs(vMIP-II-Lamp2b) represent an effective means for treating VM and show promise for clinical applications.
推荐引用方式
GB/T 7714：

Pei Weiya,Zhang Yingying,Zhu Xiaolong, et al. Multitargeted Immunomodulatory Therapy for Viral Myocarditis by Engineered Extracellular Vesicles [J].ACS NANO,2024,18(4):2782-2799.
APA：

Pei Weiya,Zhang Yingying,Zhu Xiaolong,Zhao Chen,&Lv Kun.(2024).Multitargeted Immunomodulatory Therapy for Viral Myocarditis by Engineered Extracellular Vesicles .ACS NANO,18(4):2782-2799.
MLA：

Pei Weiya, et al. "Multitargeted Immunomodulatory Therapy for Viral Myocarditis by Engineered Extracellular Vesicles" .ACS NANO 18,4(2024):2782-2799.
入库时间：

2/20/2024 3:22:09 AM
更新时间：

2/20/2024 3:22:09 AM

浏览次数：34  下载次数：0

分享到：

浏览次数：34

下载次数：0

打印次数：0